France· FR:67601314
PREVYMIS 480 mg, comprimé pelliculé
A letermovir product containing létermovir, registered in France by MERCK SHARP & DOHME (PAYS-BAS), on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Letermovir is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AX18 (letermovir), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Letermovir · ATC J05AX18
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of letermovir costs, country by country.
Normalised to the WHO defined daily dose (0.48 g), the median price runs from $9.77 in France to $563.69 in Italy — a ×58 gap.
- France: $9.77 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Letermovir · price per daily dose (0.48 g)
USD · FX 28 Sept 2026
- IT Italy$563.69
- CH Switzerland$371.41
- FR France$9.77
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- LÉTERMOVIR
- Manufacturer
- MERCK SHARP & DOHME (PAYS-BAS)
- Country
- France (FR)
- ATC code
- J05AX18
- ATC class
- Letermovir
- Defined daily dose
- 0.48 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip13340093012724728 plaquette(s) aluminium de 1 comprimé(s)EUR 8.52
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
222 interactions on record for letermovir.
Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Letermovir · interactions on record
222 records
- 38 severe
- 172 moderate
- 12 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- CilostazolB01AC23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Letermovir in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandPREVYMISOrifarm Oy
- SwitzerlandPrevymis 480 mg, FilmtablettenMSD Merck Sharp & Dohme AG
- CzechiaPREVYMISMerck Sharp & Dohme B.V., Haarlem
- SpainPREVYMIS 480 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMerck Sharp & Dohme B.V.
- IcelandPrevymisMerck Sharp & Dohme B.V.*
- NetherlandsPrevymis 480 mg, filmomhulde tablettenMerck Sharp & Dohme B.V.
- PolandPrevymisMerck Sharp & Dohme B.V.
- SwedenPREVYMIS 480 mg Filmdragerad tablettMerck Sharp & Dohme BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Prevymis
- Liechtenstein · Prevymis
- Norway · Prevymis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/00ac7ddd-3a28-4171-be37-7342b581f94e GET /v1/drugs/00ac7ddd-3a28-4171-be37-7342b581f94e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67601314",
"date_amm": "2018-01-08",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/17/1245",
"substance": "LÉTERMOVIR",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about letermovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.